BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Account Payables
Amounts the company owes suppliers for goods and services received.
BioAge Labs, Inc.NASDAQ: BIOA
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables falls 23.1% from a year ago
Account payables stood at $3.07M at the end of Q1 FY2026, down 23.1% from a year earlier and up 14.7% from the prior quarter. Over 3 fiscal years it compounded at +5.8% a year.
Context
- Account payables amounted to 0.8% of total assets at the end of Q1 FY2026, down 0.4 pp from a year earlier.
- Account payables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps falling in the next quarterly balance sheet after a -23.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 2.67M USD
- Year-over-year change
- +34.0%
- 3-year CAGR
- +5.8%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.67M | +34.0% |
| FY2024 | 2024-12-31 | 2M | +7.0% |
| FY2023 | 2023-12-31 | 1.87M | -17.5% |
| FY2022 | 2022-12-31 | 2.26M | — |
Account Payables vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -23.1% is the lowest of 9, against a peer median of +1.2%.
- Account payables amounts to 0.8% of total assets for BIOA, versus a peer median of 3.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CA$50.72M CAD | +84.7% | -24.8% | 8.4% | |
| Mar 2026 | CA$34.82M CAD | +33.4% | +3.0% | 3.1% | |
| Mar 2026 | $9.45M USD | +27.9% | +71.8% | 3.5% | |
| Mar 2026 | $6.38M USD | -1.7% | +39.1% | 4.3% | |
| Dec 2025 | $5.84M USD | — | — | 2.5% | |
| Mar 2026 | $5.08M USD | -8.8% | +50.2% | 4.6% | |
| Mar 2026 | $4.93M USD | -2.5% | -32.5% | 1.2% | |
| Mar 2026 | $4.33M USD | -20.7% | -35.1% | 2.9% | |
BIOABioAge Labs, Inc. | Mar 2026 | $3.07M USD | -23.1% | +5.8% | 0.8% |
| Mar 2026 | $1.62M USD | +4.1% | -17.4% | 1.6% | |
| Peer median (excluding BIOA) | — | +1.2% | -7.2% | 3.1% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.